(Il Sole 24 Ore Radiocor) - Milano, 8 giu - Johnson & Johnson said it had agreed to acquire the biotechnology company Firefly Bio for 1 billion dollars in cash.

The company's Firelink degrader antibody conjugate platform for KRAS-driven tumors will bolster Johnson & Johnson's oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high unmet need, Johnson & Johnson said.

The closing of the transaction is expected to occur later.

this year.

(RADIOCOR) 08-06-26 15:19:30 (0472) 5 NNNN